(Updated - March 9, 2022 7:01 AM EST)

Oppenheimer analyst Jay Olson upgraded Nektar Therapeutics (NASDAQ: NKTR) from Perform ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE